无症状疟疾感染与成人及儿童两剂Ad26.ZEBOV、MVA-BN-Filo埃博拉疫苗方案免疫应答的关系
在塞拉利昂EBOVAC-Salone埃博拉疫苗试验的子研究中,评估无症状疟疾对两剂Ad26.ZEBOV、MVA-BN-Filo方案免疫应答的影响。共587名参与者(188名成人、399名儿童),第1天无症状疟疾在成人中占47.5%、儿童中占51.5%。结论:该方案对无症状疟疾感染者具有免疫原性,接种前无需筛查无症状疟疾感染。
要点
- 第1天无症状疟疾比例:成人47.5%,儿童51.5%。
- 第1剂后,1-3岁疟疾阳性儿童GMC低于阴性儿童(GMR 0.56,95%CI 0.39-0.81)。
- 结论:该方案对无症状疟疾感染者有免疫原性,接种前无需筛查无症状疟疾。
核心结论
- Ad26.ZEBOV、MVA-BN-Filo埃博拉疫苗方案对无症状疟疾感染者具有免疫原性。
- 因此,接种该方案前无需筛查无症状疟疾感染。
研究设计与样本
- 本研究为塞拉利昂EBOVAC-Salone埃博拉疫苗试验的子研究。
- 在埃博拉疫苗接种时进行疟疾显微镜检查,有症状疟疾者在接种前接受治疗。
- 共研究587名参与者,包括188名成人(≥18岁)和399名儿童(12-17岁、4-11岁、1-3岁年龄组)。
- 第1剂后(第57天)和第2剂后(第78天)通过EBOV糖蛋白FANG酶联免疫吸附试验(ELISA)评估疫苗应答,结果以几何平均浓度(GMC)表示。
- 计算疟疾阳性与疟疾阴性参与者GMC的几何平均比值(GMR)及其95%置信区间(CI)。
主要发现
- 第1天无症状疟疾在成人中占47.5%,在儿童中占51.5%。
- 第1剂后,1-3岁疟疾阳性儿童GMC低于疟疾阴性儿童(年龄组特异性GMR 0.56;95%CI 0.39-0.81),但其他年龄组未见此差异。
- 第2剂后,各年龄组疟疾感染的影响不一致,但存在应答较低的趋势(GMR 0.82;95%CI 0.67-1.02)。
临床怎么用
- 作者结论认为,接种该方案前无需筛查无症状疟疾感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malaria infection affects the immune response to some vaccines. As Ebola virus (EBOV) outbreaks have occurred mainly in malaria-endemic countries, we have assessed whether asymptomatic malaria affects immune responses to the 2-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. METHODS: In this sub-study of the EBOVAC-Salone Ebola vaccine trial in Sierra Leone, malaria microscopy was performed at the time of Ebola vaccination. Participants with symptomatic malaria were treated before vaccination. Ebola vaccine responses were assessed post-dose 1 (day 57) and post-dose 2 (day 78) by the EBOV glycoprotein FANG enzyme-linked immunosorbent assay (ELISA), and responses expressed as geometric mean concentrations (GMCs). Geometric mean ratios (GMRs) of the GMCs in malaria-positive versus malaria-negative participants were derived with 95% confidence intervals (CIs). RESULTS: A total of 587 participants were studied, comprising 188 adults (≥18 years) and 399 children (in age groups of 12-17, 4-11, and 1-3 years). Asymptomatic malaria was observed in 47.5% of adults and 51.5% of children on day 1. Post-dose 1, GMCs were lower in 1-3-year-old malaria-positive compared with malaria-negative children (age group-specific GMR, .56; 95% CI, .39-.81) but not in older age groups. Post-dose 2, there was no consistent effect of malaria infection across the different age groups but there was a trend toward a lower response (GMR, .82; 95% CI, .67-1.02). CONCLUSIONS: The Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen is immunogenic in participants with asymptomatic malaria. Therefore, it is not necessary to screen for asymptomatic malaria infection prior to vaccination with this regimen.
引用
- Ishola D. Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children. Clin Infect Dis. 2022. PMID: 35640636. doi:10.1093/cid/ciac209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。